Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...